We are live on ! Find out more
XENE icon

Xenon Pharmaceuticals
XENE

103 hedge funds and large institutions have $671M invested in Xenon Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 29 increasing their positions, 31 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

493% more call options, than puts

Call options by funds: $3.86M | Put options by funds: $652K

300% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 4

200% more funds holding in top 10

Funds holding in top 10: 2 → 6 (+4)

14% more capital invested

Capital invested by funds: $590M → $671M (+$80.7M)

13% more funds holding

Funds holding: 91 → 103 (+12)

0.2% less ownership

Funds ownership: 82.14% → 81.94% (-0.2%)

6% less repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 31

Holders
103
Holders Change
+12
Holders Change %
+13.19%
% of All Funds
1.79%
Holding in Top 10
6
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+200%
% of All Funds
0.1%
New
16
Increased
29
Reduced
31
Closed
4
Calls
$3.86M
Puts
$652K
Net Calls
+$3.21M
Net Calls Change
+$126K

Top Buyers

1
PA
Perceptive Advisors
New York
+$21.5M
2
BC
Boxer Capital
California
+$15.8M
3
Citadel Advisors
Citadel Advisors
Florida
+$15.1M
4
CS
Candriam SCA
Luxembourg
+$13.2M
5
MWNA
Marshall Wace North America
New York
+$7.58M

Top Sellers

1
BI
BVF Inc
California
-$35.2M
2
O
OrbiMed
New York
-$21.5M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$18.9M
4
SCM
Soleus Capital Management
Connecticut
-$8.74M
5
California Public Employees Retirement System
California Public Employees Retirement System
California
-$1.25M
Name Holding Trade Value Shares
Change 		Change in
Stake
ACA
1
Avoro Capital Advisors
New York
$68M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$57.2M -$273K -14,800 -0.5%
SFM
3
Sphera Funds Management
Israel
$51.4M +$5.09M +276,130 New
PA
4
Perceptive Advisors
New York
$31.3M +$21.5M +1,163,931 +226%
BI
5
BVF Inc
California
$29.3M -$35.2M -1,910,000 -55%
Adage Capital Partners
6
Adage Capital Partners
Massachusetts
$28.4M -$18.9M -1,025,000 -40%
EAM
7
Eventide Asset Management
Massachusetts
$27.7M – – –
O
8
OrbiMed
New York
$24.8M -$21.5M -1,163,700 -47%
Capital International Investors
9
Capital International Investors
California
$19.7M – – –
Citadel Advisors
10
Citadel Advisors
Florida
$19.4M +$15.1M +820,991 +369%
NMC
11
NEA Management Company
Maryland
$18.5M – – –
Capital World Investors
12
Capital World Investors
California
$17.9M – – –
DCM
13
Driehaus Capital Management
Illinois
$17.6M +$3.2M +173,725 +23%
Bank of New York Mellon
14
Bank of New York Mellon
New York
$17.4M -$417K -22,611 -2%
Point72 Asset Management
15
Point72 Asset Management
Connecticut
$16.8M +$2.6M +141,299 +19%
BC
16
Boxer Capital
California
$16M +$15.8M +857,000 New
GTC
17
Ghost Tree Capital
New York
$15.8M – – –
BBA
18
Baker Bros. Advisors
New York
$14M – – –
CS
19
Candriam SCA
Luxembourg
$13.3M +$13.2M +715,722 New
Renaissance Technologies
20
Renaissance Technologies
New York
$12.3M -$645K -35,000 -5%
IC
21
Ikarian Capital
Texas
$11.9M +$553 +30 +0%
SCM
22
Suvretta Capital Management
New York
$11.1M +$2.84M +154,047 +35%
RSCM
23
Rock Springs Capital Management
Maryland
$10.7M – – –
ACP
24
Acuta Capital Partners
California
$7.77M +$90.5K +4,909 +1%
BlackRock
25
BlackRock
New York
$7.66M +$242K +13,129 +3%
1
2 3 4 5

XENE Hedge Fund Activity: Q2 2021 in Review

103 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q2 2021, worth a combined $671M — up 14% from $590M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new XENE positions and 4 closed out — a net gain of 12 holders — while 29 added to existing stakes and 31 trimmed.

The largest buyer was Perceptive Advisors, adding an estimated $21.5M. The largest seller was BVF Inc, cutting an estimated $35.2M.

  • 103 institutional investors held Xenon Pharmaceuticals (XENE) as of Q2 2021, up from 91 in Q1 2021.
  • Funds reported $671M of Xenon Pharmaceuticals stock for Q2 2021, up 14% quarter-over-quarter.
  • 16 funds opened new Xenon Pharmaceuticals positions in Q2 2021 and 4 closed out, a net change of +12 holders.
  • The largest Xenon Pharmaceuticals buyer in Q2 2021 was Perceptive Advisors, an estimated $21.5M added.
  • The largest Xenon Pharmaceuticals seller in Q2 2021 was BVF Inc, an estimated $35.2M sold.

Based on aggregated 13F filings for Q2 2021.